RCReports CornerPharmaceutical Market: India A ComprehensiveIndustry Analysis
DescriptionDescriptionReports Cornerwww.reportscorner.com1.0 Summary"Pharmaceutical Market: India, A Competitive Industry ...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com1.0 Summary"Pharmaceutical Market: India, A Competitive Indus...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThis report describes the current therapeutics that are prope...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comStrategic drivers and restraints of this market are revealed ...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• To comprehensive review and analyse financial and productde...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Knowledge of how the Indian biopharma market will integrate...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe study provides a comprehensive description of currentcomp...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comWith many years of medical writing and publishing the author ...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comFinancial and business environment sources such as the WorldT...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comTherefore a market shift from acute therapeutics to chronicme...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe IPM is divided into four key areas - active pharmaceutica...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThis is a 17% increase from 77 million in 2001. Noncommunicab...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Cardiovascular deaths will increase from 2.7 million in 200...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comIndia’s Twelfth Five Year Plan (12th 5YP) aims to increase fu...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Intellectual Property (IP) technology transfer• Nanotechnol...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comAlmost $30 billion of Indian pharmaceutical products wereexpo...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe Indian Contract Research and Manufacturing Service(CRAMS)...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Ranbaxy• Piramal• Zydus Cadila• Mankind• LupinOver the next...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Cumulative exports recorded during 2011-12 were $242 billio...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Anti-Diabetic• Neuro/CNS• Dermatology• GynaecologyKelly Sci...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe12th 5YP also proposes to increase the output of scientifi...
Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Aurobindo Pharma• Bharat Serums and Vaccines Ltd• Biocon Bi...
Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com1.0 Summary1.1 Objectives of Report1.2 Scope of Study...
Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com2.9 Diabetes2.10 Cancer2.11 Chronic Respiratory Disea...
Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com5.5 Contract Research and Manufacturing Service (CRAM...
Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com6.11 Ranbaxy Laboratories6.12 Reliance Life Sciences6...
Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com8.4 Cipla8.5 Divis laboratories8.6 Dr Reddy’s Laborat...
For more informationFor more informationReports Cornerwww.reportscorner.comFor more information please visit our websiteht...
Reports CornerThank YouThank Youwww.reportscorner.comRCContact us: contact@reportscorner.com
Upcoming SlideShare
Loading in...5
×

Pharmaceutical market india a comprehensive industry analysis - Reports Corner

909

Published on

"1.0 Summary

“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.

The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.


This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
909
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
60
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Pharmaceutical market india a comprehensive industry analysis - Reports Corner

  1. 1. RCReports CornerPharmaceutical Market: India A ComprehensiveIndustry Analysis
  2. 2. DescriptionDescriptionReports Cornerwww.reportscorner.com1.0 Summary"Pharmaceutical Market: India, A Competitive Industry Analysis"by Kelly Scientific Publications is a comprehensive report on thepharmaceutical and biotechnology industry in India and its impacton international markets. This report scrutinises top Indianpharmacos and their battle within domestic and internationaltherapeutic markets. The business environment in which theycompete is analysed as are key drivers, constraints, challengesand opportunities.The Indian pharmaceutical market is set to become the eightlargest pharma market globally by 2015. In 2012 it was worth $13billion. It is forecast to reach $50 billion by 2015 and increase itsdominance as a leading player in Asia. It is predicted that theIndian pharma market will be a significant global competitor by2020 with an expected worth of up to $74 billion.
  3. 3. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com1.0 Summary"Pharmaceutical Market: India, A Competitive Industry Analysis"by Kelly Scientific Publications is a comprehensive report on thepharmaceutical and biotechnology industry in India and its impacton international markets. This report scrutinises top Indianpharmacos and their battle within domestic and internationaltherapeutic markets. The business environment in which theycompete is analysed as are key drivers, constraints, challengesand opportunities.The Indian pharmaceutical market is set to become the eightlargest pharma market globally by 2015. In 2012 it was worth $13billion. It is forecast to reach $50 billion by 2015 and increase itsdominance as a leading player in Asia. It is predicted that theIndian pharma market will be a significant global competitor by2020 with an expected worth of up to $74 billion.
  4. 4. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThis report describes the current therapeutics that are propellingthe biopharmaceutical market in India. It examines the currenteconomic climate and how India compares to other emergingmarkets and also evolved markets such as the US and Europe.Current developments relating to patent expirations, governmentfunding, and regulations are discussed. The emerging trends thatappear in key sub-markets such as generics, oncology,cardiovascular, diabetes and vaccines are elucidated andanalysed.This study reveals market figures of the overall Indianpharmaceutical market and sub-markets. Forecast projections andfuture growth rates are provided to give the reader a forthcomingperspective of this growing industry.The study also provides a comprehensive financial and productreview of key players in the biopharmaceutical industry in India.
  5. 5. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comStrategic drivers and restraints of this market are revealed andmarket opportunities and challenges are identified.In summary, the Indian biopharmaceutical market has hugeopportunities for growth. This industry will significantly affect theinternational healthcare market and has enormous potential forinvestment.1.1 Objectives of ReportThe main objectives of this report are:• To comprehensively summarize current developments in theIndian biopharmaceutical industry.• To identify emerging trends in key markets and sub-marketssuch as biogenerics, cardiology, oncology therapeutics, diabeticcare, vaccines and anti-infective agents.
  6. 6. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• To comprehensive review and analyse financial and productdetails of key players in the industry• To present market figures of the current Indianbiopharmaceutical market value and give forecast projections andgrowth rates• To identify key drivers and restraints of the Indianbiopharmaceutical market• To report and analyse market opportunities and challenges• To identify funding and government sponsorship issuesThe reader of this report will gain:• An in-depth understanding of the Indian biopharmaceuticalmarket and it’s environment• Current market facts, figures and product lines of key players inthe industry• An insight into how generic therapeutics will propagate theIndian biopharmaceutical market
  7. 7. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Knowledge of how the Indian biopharma market will integrateinto the global healthcare market• Information on key government policies• Data on levels of private and publically funded biopharmastudies in India• Strategies on how to adapt and restructure current businessmodels to this industry1.2 Scope of StudyThe Indian pharmaceutical market is the main driver of thecountry’s healthcare industry The Indian Pharmaceutical Industry(IPI) is divided into four main sectors:• Active Pharmaceutical Ingredients (APIs)• Contract Research and Manufacturing Services (CRAMS)• Formulations• Biosimilars
  8. 8. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe study provides a comprehensive description of currentcompanies with an interest in the Indian market and their financialand product portfolios. This paper also identifies key therapeuticsthat are driving the biopharma market in India and currentrestraints and challenges that may weaken this emergingindustry.1.3 Data Sources and MethodologyThe project leader and author of this research obtained a Ph.D. inMedicine from the Royal College of Surgeons in Ireland, followingcompletion of a M.Sc. in Biotechnology (NUIG) and an honoursdegree in Biochemistry from Trinity College Dublin. She hasextensive experience in drug target discovery and vaccineresearch and development and conducted post-doctoral studiesand lecturing in Trinity College Dublin. The author’s career spansboth industry and academia where she has worked with both startup biotech and multinational pharmaceutical companies.
  9. 9. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comWith many years of medical writing and publishing the author alsohas extensive experience and knowledge of genetics, molecularbiology, immunology, bioinformatics and diagnostic testing. As apharma/biotech industry analyst she has significant expertise inlaboratory diagnostic testing and instrument and reagentdevelopment technology.Sources of information for this report were collected andcompiled from company specific corporate websites, annualreports, press-releases, international scientific and medicaljournals and news and research reports. Graphical and numericaldata have been referenced and sourced accordingly. Specificwebsites were consulted and referenced throughout thecompletion of this report including that of the World HealthOrganization (www.who.int) and European Medicines Agency(www.ema.europa.eu).
  10. 10. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comFinancial and business environment sources such as the WorldTrade Organization (www.WTO.org) and the InternationalMonetary Fund (www.IMF.org) and other government agenciesworldwide were also accessed. Kelly Scientific Publications hasused the most recent statistical and numerical data available. Themost reliable of data sources were used in the production of thisreport, however we cannot guarantee complete accuracy orcompleteness from secondary information sources.1.4 Key Findings and ObservationsIn 2012 the Indian pharmaceutical market was worth $13 billionand is forecast to become the eight largest pharma marketglobally by 2015. It is a significant player in emerging markets.This growth fuelled by the significant level of chronic disease inthe country which is estimated at 20% of the population. Over 50%of deaths are due to chronic diseases such as cancer,cardiovascular disease and diabetes in India.
  11. 11. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comTherefore a market shift from acute therapeutics to chronicmedications will occur in the coming years. Vaccine productionand generic drug manufacturing are key products for the Indianmarket and Kelly Scientific Publications predict that internationalmarkets will be significantly penetrated with these products in thenear future.The government in India has identified biotechnology as a keyarea of growth and to that end has provided significant fundingfor opportunities within this area. India’s Twelfth Five Year Plan(12th 5YP) will function to increase private investment in R&D andinternational collaborations. The overall aim is to position India asone of the top five scientific superpowers by 2020.The Indian pharma market is fragmented and up to 40% of it isdominated by a small number of players including Cipla, GSK,Sun Pharma, Ranbaxy and Piramal.
  12. 12. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe IPM is divided into four key areas - active pharmaceuticalingredients (APIs), contract research and manufacturing services(CRAMS), formulations and biosimilars. The market is currentlycontrolled by acute therapy which demanded 73% of total in 2012.This is forecast to decrease over the coming years as lifestyle andchronic disease increase further in prevalence.1.5 Executive SummaryToday, India is the second largest country and is populated bymore than 1.2 billion. By 2050, it is estimated that the populationwill have grown to between 1.6-1.8 billion and so key investmentsand strategies to exploit this growing market is paramount. India’spotential as a key player in the pharma market is significant.The population of India over 60 years old is forecast to reach 300million by 2050.
  13. 13. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThis is a 17% increase from 77 million in 2001. Noncommunicablediseases (NCDs) such as heart disease, stroke, cancer, chronicrespiratory disease, diabetes, mental health issues, vision andhearing difficulties will all increase in incidence with thispopulation growth and put pressure on health services. Accordingto the World Health Organisation (WHO), 80% of adult deaths aredue to NCDs in urban centres and 60% of deaths in rural areas.Over 20% of the Indian population are currently suffering from achronic disease and 10% have comorbidities. Chronic diseasescause 50% of all deaths in India. Infectious and parasitic diseasesare a significant contributor, as are cardiovascular diseases,respiratory conditions, cancer and diabetes. According to a studyby Patel et al in The Lancet, almost 75% of all deaths in India willbe due to a chronic disease in 2030.• Cancer fatalities will rise from 730,000 in 2004 to 1.5 million in2030.
  14. 14. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Cardiovascular deaths will increase from 2.7 million in 2004 to 4million in 2030.• Coronary heart disease deaths will increase from 7.1 million in2004 to 17.9 million in 2030.Today, the top causes of mortality in India are:• Cardiovascular diseases• Cancers• Chronic Respiratory Disease• Respiratory infections• Perinatal Conditions• Diarrhoeal diseases• Digestive diseases• HIV/AIDS• Tuberculosis
  15. 15. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comIndia’s Twelfth Five Year Plan (12th 5YP) aims to increase fundingfor six areas of scientific research and development until 2017. Aninvestment of INR 1,204 billion (US $24 billion) will increase IndianR&D and boost its credibility internationally. The plan alsoproposes to increase the output of scientific papers from 3%globally in 2012 to 5% in 2017. Biotechnology will receivesignificant funding and the following areas will expand over thecoming years:• Molecular and cell biology• Structural biology• Immunology• Neurobiology• Bioengineering• Clinical and translational research• Regulatory sciences
  16. 16. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Intellectual Property (IP) technology transfer• Nanotechnology• NanotechnologyThe Indian Pharmaceutical market (IPM) is one of the mostimportant emerging pharma markets and in 2012 was worth $13billion. It is forecast to increase dramatically to $74 billion by 2020and increase its dominance as a leading player in Asia.The IPM is a significant driver of the domestic healthcare industryand is divided into four main sections:• Active Pharmaceutical Ingredients (APIs)• Contract Research and Manufacturing Services (CRAMS)• Formulations• Biosimilars
  17. 17. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comAlmost $30 billion of Indian pharmaceutical products wereexported during 2011-2012 and this is expected to hit $50 billionby 2015. The majority of exports are bulk drugs (including APIs)which contribute over 50% share. Currently, Indian bulk drugexports demand 9% of the global bulk drug market. India mainlyexports to the US, which received 27% of exported APIs in 2012.This was followed by the EU (19%) and Africa (17%).The Indian formulations market exported $8 billion during 2011-2012 and is set to reach $14 billion by 2015. The domesticformulation market consumes 80% of product manufactured andwas worthAlmost $11 billion in 2012. This will rise to $16 billion by 2015.Currently the Indian biosimilar market share is low at 3% of theglobal market ($1 billion). However between 2013-2015 it isforecast to grow strongly and demand 20-25% of the globalbiosimilar market. By 2015, the global biosimilar market isexpected to reach $10 billion.
  18. 18. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe Indian Contract Research and Manufacturing Service(CRAMS) industry is currently worth $7.6 billion. It is divided intomanufacturing and research, with manufacturing servicesaccounting for just over 60% of Indian business. Between 2010and 2012, the Indian CRAMS industry grew by 41% due to a largeincrease in outsourcing. This growth rate is triple the globalaverage of growth rate of 12.6%. By 2015, it is forecast that theCRAMS industry in India will hit $7.8-8 billion, fuelled by theimpending patent cliff and high requirement for genericmanufacturing, biologics, and drug delivery technologies.The Indian pharma market is fragmented and up to 40% of it isdominated by a small number of players including:• Cipla• GSK• Sun Pharma
  19. 19. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Ranbaxy• Piramal• Zydus Cadila• Mankind• LupinOver the next number of years, it is expected that the IPM willcontinue to grow to as much as $74 billion by 2020 with a CAGRof between 14-16%. Therefore by 2020, the IPM will becomparable to other developed pharma markets (excluding the USand Japan) and also to the Chinese pharma market. Significanteconomic indicators that will propel the IPM in the near futureinclude:• India is one of the fastest growing economies globally with a16% growth increase in its pharmaceutical market 2012• India’s sovereign credit rating rose by 2.98% during the period2007-12
  20. 20. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Cumulative exports recorded during 2011-12 were $242 billion - agrowth of 23%• Imports in 2011-12 at $391 billion – a growth of 29%The Indian pharma market is currently dominated by the acutetherapy market which demanded 73% of total in 2012. This isforecast to decrease over the coming years as lifestyle andchronic disease increase further in prevalence. In 2012, the anti-infectives market held the premier position within the IPM, with16.1% share. The following therapeutic areas all hold significantmarket share within the IPM:• Anti-infectives• Cardiac• Gastro Intestinal• Respiratory• Pain/Analgesics• Vitamins/Minerals/Nutrients
  21. 21. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Anti-Diabetic• Neuro/CNS• Dermatology• GynaecologyKelly Scientific Publications believes that chronic markets such ascardiovascular, diabetes and neurology/psychiatry will allcontribute to market penetration within the next five years and willmaintain a fast growth rate. A shift towards disease managementand prevention will steadily cause a shift in the Indian pharmamarket from acute to chronic areas.India’s Twelfth Five Year Plan (12th 5YP) aims to increase fundingfor six areas of scientific research and development until 2017.The Indian Government has proposed an investment of INR 1,204billion (US $24 billion) to strategically increase the number of PhDgraduates, researchers and essentially boost internationalrecognition for Indian R&D.
  22. 22. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe12th 5YP also proposes to increase the output of scientificpapers from 3% globally in 2012 to 5% in 2017. The overall aim isto position India as one of the top five scientific superpowers by2020. In order to do this information gathered from R&D must becommercialized and current pharma/biotech companies situatedin India must increase their interests in R&D. By 2017, it isenvisaged that the ratio of private : public share of investments is50:50.This report highlights a number of significant Indian pharmacosand gives details of their operations, products, financials andbusiness strategy. The following companies were chosen foranalysis as they have specific advantages that we believe willdrive the pharmaceutical industry in India.
  23. 23. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com• Aurobindo Pharma• Bharat Serums and Vaccines Ltd• Biocon Biopharmaceuticals• Cipla• Divis Laboratories• Dr Reddy’s Laboratories• Lupin• Mankind Pharma• Panacea Biotech• Piramal Group• Ranbaxy Laboratories• Reliance Life Sciences• Serum Institute of India• Sun Pharmaceuticals• Zydus Cadila
  24. 24. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com1.0 Summary1.1 Objectives of Report1.2 Scope of Study1.3 Data Sources and Methodology1.4 Key Findings and Observations1.5 Executive Summary2.0 Epidemiology and Disease Overview2.1 Cardiovascular Disease2.2 Infectious Disease2.3 Respiratory Infections2.4 Tuberculosis2.5 HIV2.6 Hepatitis2.7 Typhoid Fever2.8 Dengue Fever
  25. 25. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com2.9 Diabetes2.10 Cancer2.11 Chronic Respiratory Disease- Asthma and COPD3.0 Twelfth Five Year Plan – A Boost for Scientific Research and Development4.0 Economic and Business Environment4.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics4.2 Gross Domestic Product of India, Historic and Projection Analysis4.3 Global and India Economic Outlook 2010-20134.4 Indian Economic Outlook in Comparison to Advanced Economies (US, Europe)5.0 Indian Pharmaceutical Industry5.1 Overview5.2 Formulations Market5.3 Active Pharmaceutical Ingredient Market5.4 Biosimilar Market
  26. 26. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com5.5 Contract Research and Manufacturing Service (CRAMS)5.6 Indian Pharmaceutical Industry Market5.7 Evaluation of Market Share by Therapeutic Area5.8 Key Players6.0 Indian Pharmaceutical Company Profiles and Financial Data6.1 Aurobindo Pharma6.2 Bharat Serums and Vaccines Ltd6.3 Biocon Biopharmaceuticals6.4 Cipla6.5 Divis Laboratories6.6 Dr Reddy’s Laboratories6.7 Lupin6.8 Mankind Pharma6.9 Panacea Biotech6.10 Piramal Group
  27. 27. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com6.11 Ranbaxy Laboratories6.12 Reliance Life Sciences6.13 Serum Institute of India6.14 Sun Pharmaceuticals6.15 Zydus Cadila7.0 SWOT Analysis of Indian Pharmaceutical Market7.1 Growth Factors7.2 Strengths of Indian Pharmaceutical Industry7.3 Main Weaknesses7.4 Significant Opportunities within the Indian Pharmaceutical Industry7.5 Threats and Considerations8.0 Company Directory and Key People8.1 Aurobindo Pharma8.2 Bharat Serums and Vaccines Ltd8.3 Biocon Biopharmaceuticals
  28. 28. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com8.4 Cipla8.5 Divis laboratories8.6 Dr Reddy’s Laboratories8.7 Lupin8.8 Panacea Biotech8.9 Reliance Life Sciences9.0 Appendix9.1 Comprehensive List of Pharmaceutical Company’s in India
  29. 29. For more informationFor more informationReports Cornerwww.reportscorner.comFor more information please visit our websitehttps://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
  30. 30. Reports CornerThank YouThank Youwww.reportscorner.comRCContact us: contact@reportscorner.com
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×